worth another thoughtHello all first , my hats off to notable.He/ she has put out a lot of effort to detail the various advantages & applications of Pelareorep. That being clinical information as to why & how Pela works & why better co- therapy with some drugs & not others. As always, I direct readers to the oncolyitics biotech web site. They have a great presentation designed to " try" to explain the various in- place proven results & a focus to the future opportunities. I say " try" Cancer is a very complicated disease. Almost every type, has sub types. and our bodies react differently to treatments. Simply put not all drugs/ therapies work for everyone. So just for starters , we have a very complex disease, then add in unlimited variables with the patients. Leaving drug developments with unimaginable complex outcomes. Drug companies after getting approval, need to market, manufacture & distribute product XYZ. Pelareorep has full scale in- place approved production capacity. The production cost is minimal. Where the cost is , getting to the approval. Right now, Onc has fast track designation for Pelareorep to be used for Pancreatic cancer & one type of breast cancer. They do not yet have marketing approval. The recent news release clearly indicates they are in- process of defining & starting a potential enabling study, with accelerated approval indications. What does that mean? First, understand ALL of ONCs activities are moderated alongside the FDA. The pancreatic cancer trials are alongside Roche. Those who enjoy bashing mangemet need to please inform Roche of your extream intelligence, as they obviously missed something? Respectfully , Roche would not risk their good name , or their lead cancer product alongside oncolytics without massive due diligence. Then again the upcoming additional arm added to the Gobblet studies ( G.I. Cancers), was the direct result of a competive application. From that Onc was granted $5million, moving forward the upcoming enabling study will be managed by CGAR, a global pancreatic cancer agency. what does accelerated approval mean? Once the studies are started, They can use previous study data & if certain milestones met, product approval can be granted, prior to completion. Saving years of study time & obviously $$$$. simple put, Onc is we'll set to move forward. yes they still need a $$ partner for the MBc trial. or a complete buyout. Shareholder value? As notable pointed out the company that just did a pharma deal with $850mill upfront, was not even a listed company. The value is in the potential market of the product. onc is a lot closer to that now than ever. Slow, complex....absolutely. should they get approved , yes $billions take care Comment on this Post 3 Likes Quote Share IconShare Report IconAbuse < previous="" bullboard="" posts="" next="">> Dealroom for high-potential pre-IPO opportunities Interested in these industries and sectors? Receive investor kits and email updates from Stockhouse and directly from these companies. Healthcare All None Theralase Technologies Inc. Indiva Ltd Gemina Laboratories Ltd. Consumer Cyclical All None Metals & Mining All None Energy All None Communication Services All None Your current email: bgaugreau@cogeco.ca I consent to receiving investment related electronic messages from Stockhouse and the companies selected. I may withdraw my consent at any time. Submit Featured News Links Discover the Latest in Advanced Investing Tools for Trading Options How to Trade on the Stock Market: A Beginners Guide October 16 & 17: Red Cloud Fall Mining Showcase 2024 Sign Up Here One of the Best Venture Pharma Stocks has Grown even Stronger Energy Co. Secures $52 Million Credit Facility and Launches Fall Drilling Program to Accelerate Growth at Two Rivers East Prospera Energy Inc. Announces Cash Flow Optimization Viva Gold Brings New Drill Program and Updated PEA to Nevada Project World Class, High Quality Diamond Project: 66 Million Carats Over a 38-Year Mine Life - Learn More Here Stockhouse Logo About Us Careers Contribute Contact Us Support Help Legal Disclaimer Privacy Policy Follow Us Stockhouse.com is owned by Stockhouse Publishing Ltd. 2019 Stockhouse Publishing Ltd. All rights reserved. Financial Market Data powered by Refinitiv. All rights reserved. Quotes and other data delayed by 15 minutes for NYSE/AMEX/NASDAQ, 20 minutes for TSX/TSX-V unless otherwise indicated. Google Play and the Google Play logo are trademarks of Google Inc. The Apple logo and iTunes are trademarks of Apple Inc., registered in the U.S. and other countries.